Search

Your search keyword '"Girelli Francesco"' showing total 6 results
Start Over Author "Girelli Francesco" Publisher mdpi ag
6 results on '"Girelli Francesco"'

1. Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study

Author

Paroli, Marino, primary, Becciolini, Andrea, additional, Bravi, Elena, additional, Andracco, Romina, additional, Nucera, Valeria, additional, Parisi, Simone, additional, Ometto, Francesca, additional, Lumetti, Federica, additional, Farina, Antonella, additional, Del Medico, Patrizia, additional, Colina, Matteo, additional, Lo Gullo, Alberto, additional, Ravagnani, Viviana, additional, Scolieri, Palma, additional, Larosa, Maddalena, additional, Priora, Marta, additional, Visalli, Elisa, additional, Addimanda, Olga, additional, Vitetta, Rosetta, additional, Volpe, Alessandro, additional, Bezzi, Alessandra, additional, Girelli, Francesco, additional, Molica Colella, Aldo Biagio, additional, Caccavale, Rosalba, additional, Di Donato, Eleonora, additional, Adorni, Giuditta, additional, Santilli, Daniele, additional, Lucchini, Gianluca, additional, Arrigoni, Eugenio, additional, Platè, Ilaria, additional, Mansueto, Natalia, additional, Ianniello, Aurora, additional, Fusaro, Enrico, additional, Ditto, Maria Chiara, additional, Bruzzese, Vincenzo, additional, Camellino, Dario, additional, Bianchi, Gerolamo, additional, Serale, Francesca, additional, Foti, Rosario, additional, Amato, Giorgio, additional, De Lucia, Francesco, additional, Dal Bosco, Ylenia, additional, Foti, Roberta, additional, Reta, Massimo, additional, Fiorenza, Alessia, additional, Rovera, Guido, additional, Marchetta, Antonio, additional, Focherini, Maria Cristina, additional, Mascella, Fabio, additional, Bernardi, Simone, additional, Sandri, Gilda, additional, Giuggioli, Dilia, additional, Salvarani, Carlo, additional, Franchina, Veronica, additional, Molica Colella, Francesco, additional, Ferrero, Giulio, additional, and Ariani, Alarico, additional

Published
2023
Full Text
View/download PDF

2. Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting: An Italian Multicenter Study

Author

Lo Gullo, Alberto, primary, Becciolini, Andrea, additional, Parisi, Simone, additional, Del Medico, Patrizia, additional, Farina, Antonella, additional, Visalli, Elisa, additional, Dal Bosco, Ylenia, additional, Molica Colella, Aldo, additional, Lumetti, Federica, additional, Caccavale, Rosalba, additional, Scolieri, Palma, additional, Andracco, Romina, additional, Girelli, Francesco, additional, Bravi, Elena, additional, Colina, Matteo, additional, Volpe, Alessandro, additional, Ianniello, Aurora, additional, Ditto, Maria, additional, Nucera, Valeria, additional, Franchina, Veronica, additional, Platé, Ilaria, additional, Di Donato, Eleonora, additional, Amato, Giorgio, additional, Salvarani, Carlo, additional, Bernardi, Simone, additional, Lucchini, Gianluca, additional, De Lucia, Francesco, additional, Molica Colella, Francesco, additional, Santilli, Daniele, additional, Mansueto, Natalia, additional, Ferrero, Giulio, additional, Marchetta, Antonio, additional, Arrigoni, Eugenio, additional, Foti, Rosario, additional, Sandri, Gilda, additional, Bruzzese, Vincenzo, additional, Paroli, Marino, additional, Fusaro, Enrico, additional, and Ariani, Alarico, additional

Published
2023
Full Text
View/download PDF

3. Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study

Author

Becciolini, Andrea, primary, Parisi, Simone, additional, Del Medico, Patrizia, additional, Farina, Antonella, additional, Visalli, Elisa, additional, Molica Colella, Aldo Biagio, additional, Lumetti, Federica, additional, Caccavale, Rosalba, additional, Scolieri, Palma, additional, Andracco, Romina, additional, Girelli, Francesco, additional, Bravi, Elena, additional, Colina, Matteo, additional, Volpe, Alessandro, additional, Ianniello, Aurora, additional, Ditto, Maria Chiara, additional, Nucera, Valeria, additional, Franchina, Veronica, additional, Platè, Ilaria, additional, Donato, Eleonora Di, additional, Amato, Giorgio, additional, Salvarani, Carlo, additional, Bernardi, Simone, additional, Lucchini, Gianluca, additional, De Lucia, Francesco, additional, Molica Colella, Francesco, additional, Santilli, Daniele, additional, Mansueto, Natalia, additional, Ferrero, Giulio, additional, Marchetta, Antonio, additional, Arrigoni, Eugenio, additional, Foti, Rosario, additional, Sandri, Gilda, additional, Bruzzese, Vincenzo, additional, Paroli, Marino, additional, Fusaro, Enrico, additional, and Ariani, Alarico, additional

Published
2023
Full Text
View/download PDF

4. Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis

Author

Becciolini, Andrea, primary, Parisi, Simone, additional, Caccavale, Rosalba, additional, Bravi, Elena, additional, Lumetti, Federica, additional, Andracco, Romina, additional, Volpe, Alessandro, additional, Gardelli, Lucia, additional, Girelli, Francesco, additional, Di Donato, Eleonora, additional, Santilli, Daniele, additional, Lucchini, Gianluca, additional, Ditto, Maria Chiara, additional, Platè, Ilaria, additional, Arrigoni, Eugenio, additional, Mozzani, Flavio, additional, Riva, Michele, additional, Marchetta, Antonio, additional, Fusaro, Enrico, additional, Sandri, Gilda, additional, Salvarani, Carlo, additional, Paroli, Marino, additional, and Ariani, Alarico, additional

Published
2022
Full Text
View/download PDF

5. Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study

Author

Parisi, Simone, primary, Becciolini, Andrea, additional, Ditto, Maria Chiara, additional, Rozza, Davide, additional, Zanetti, Anna, additional, Laganà, Angela, additional, Peroni, Clara Lisa, additional, Centanaro Di Vittorio, Chiara, additional, Degiovanni, Rosanna, additional, Realmuto, Cristina, additional, Scirè, Carlo Alberto, additional, Priora, Marta, additional, Di Donato, Eleonora, additional, Santilli, Daniele, additional, Mozzani, Flavio, additional, Lucchini, Gianluca, additional, Ariani, Alarico, additional, Gardelli, Lucia, additional, Girelli, Francesco, additional, Arrigoni, Eugenio, additional, Platè, Ilaria, additional, Bravi, Elena, additional, Paroli, Marino, additional, Caccavale, Rosalba, additional, Salvarani, Carlo, additional, Sandri, Gilda, additional, Lumetti, Federica, additional, Volpe, Alessandro, additional, Marchetta, Antonio, additional, and Fusaro, Enrico, additional

Published
2022
Full Text
View/download PDF

6. Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in Italy.

Author

Paroli M, Becciolini A, Lo Gullo A, Parisi S, Bravi E, Andracco R, Nucera V, Ometto F, Lumetti F, Farina A, Del Medico P, Colina M, Ravagnani V, Scolieri P, Larosa M, Priora M, Visalli E, Addimanda O, Vitetta R, Volpe A, Bezzi A, Girelli F, Molica Colella AB, Caccavale R, Di Donato E, Adorni G, Santilli D, Lucchini G, Arrigoni E, Platè I, Mansueto N, Ianniello A, Fusaro E, Ditto MC, Bruzzese V, Camellino D, Bianchi G, Serale F, Foti R, Amato G, De Lucia F, Dal Bosco Y, Foti R, Reta M, Fiorenza A, Rovera G, Marchetta A, Focherini MC, Mascella F, Bernardi S, Sandri G, Giuggioli D, Salvarani C, De Andres MI, Franchina V, Molica Colella F, Ferrero G, Raffeiner B, and Ariani A

Abstract

Background/Objectives: The Janus kinase inhibitors (JAKi) tofacitinib (TOFA), baricitinib (BARI), upadacitinib (UPA), and filgotinib (FILGO) are effective drugs for the treatment of rheumatoid arthritis. However, the US Food and Drug Administration (FDA) raised concerns about the safety of TOFA after its approval. This prompted the European Medicines Agency (EMA) to issue two safety warnings for limiting TOFA use, then extended a third warning to all JAKi in patients at high risk of developing serious adverse effects (SAE). These include thrombosis, major adverse cardiac events (MACE), and cancer. The purpose of this work was to analyze how the first two safety warnings from the EMA affected the prescribing of JAKi by rheumatologists in Italy. Methods: All patients with rheumatoid arthritis who had been prescribed JAKi for the first time in a 36-month period from 1 July 2019, to 30 June 2022 were considered. Data were obtained from the medical records of 29 Italian tertiary referral rheumatology centers. Patients were divided into three groups of 4 months each, depending on whether the JAKi prescription had occurred before the EMA's first safety alert (1 July-31 October 2019, Group 1), between the first and second alerts (1 November 2019-29 February 2020, Group 2), or between the second and third alerts (1 March 2021-30 June 2021, Group 3). The percentages and absolute changes in the patients prescribed the individual JAKi were analyzed. Differences among the three groups of patients regarding demographic and clinical characteristics were also assessed. Results: A total of 864 patients were prescribed a JAKi during the entire period considered. Of these, 343 were identified in Group 1, 233 in Group 2, and 288 in Group 3. An absolute reduction of 32% was observed in the number of patients prescribed a JAKi between Group 1 and Group 2 and 16% between Group 1 and Group 3. In contrast, there was a 19% increase in the prescription of a JAKi in patients between Group 2 and Group 3. In the first group, BARI was the most prescribed drug (227 prescriptions, 66.2% of the total), followed by TOFA (115, 33.5%) and UPA (1, 0.3%). In the second group, the most prescribed JAKi was BARI (147, 63.1%), followed by TOFA (65, 27.9%) and UPA (33, 11.5%). In the third group, BARI was still the most prescribed JAKi (104 prescriptions, 36.1%), followed by UPA (89, 30.9%), FILGO (89, 21.5%), and TOFA (33, 11.5%). The number of patients prescribed TOFA decreased significantly between Group 1 and Group 2 and between Group 2 and Group 3 ( p ˂ 0.01). The number of patients who were prescribed BARI decreased significantly between Group 1 and Group 2 and between Group 2 and Group 3 ( p ˂ 0.01). In contrast, the number of patients prescribed UPA increased between Group 2 and Group 3 ( p ˂ 0.01). Conclusions : These data suggest that the warnings issued for TOFA were followed by a reduction in total JAKi prescriptions. However, the more selective JAKi (UPA and FILGO) were perceived by prescribers as favorable in terms of the risk/benefit ratio, and their use gradually increased at the expense of the other molecules.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results